

## CASE REPORT / ПРИКАЗ БОЛЕСНИКА

# Challenges in the treatment of hypotension in an extremely preterm neonate

Ilija Palić, Biljana Jovanović Krišulović, Marija Jovičić, Miroslava Kostić Todorović

Institute of Neonatology, Belgrade, Serbia

**SUMMARY**

**Introduction** Hypotension is often seen in preterm neonates, as a result of various factors such as immature myocardium, transitional circulation, perinatal hypoxia, positive-pressure ventilation, and relative adrenal insufficiency. The leading causes of hypotension in preterm neonates are sepsis and septic shock, patent ductus arteriosus (PDA), and necrotizing enterocolitis.

**Case outline** The female preterm neonate was delivered at 24<sup>1/7</sup> weeks of gestation with a birth weight of 710 g and an Apgar score of 3 in the first minute after birth. Hypotension was noted from the first day of life, so dopamine was administered. The neonate was admitted to the Institute of Neonatology on the fourth day of life and we continued dopamine and dobutamine. Despite increasing the dose, the hypotension remained persistent, and we started epinephrine. Echocardiography showed PDA and signs of heart failure. The neonate's condition was complicated by acute renal injury. Therefore, ibuprofen was not used to close the PDA, so we continued its conservative treatment. In order to correct the hypotension, hydrocortisone was added to the therapy. Despite conservative treatment of the PDA, hypotension was persistent and severe, and its treatment lasted for four weeks of hospitalization. After achieving hemodynamic and respiratory stability, surgical ligation of the PDA was performed.

**Conclusion** Hypotension is a complication in the early neonatal period in an extremely preterm neonate. Knowing the cause, as well as the pathophysiology, allows for the selection of the appropriate drug and proper treatment of hypotension in preterm neonates, which is very challenging for neonatologists.

**Keywords:** premature newborn; ductus arteriosus; hypotension; cardiovascular agents

**INTRODUCTION**

Hypotension is often encountered in preterm neonates. Various factors are associated with hypotension in preterm neonates such as immature myocardium, transitional circulation, perinatal hypoxia, positive-pressure ventilation (PPV) after birth and transient or relative adrenal insufficiency. The leading causes of hypotension in preterm neonates are sepsis and septic shock, patent ductus arteriosus PDA and necrotizing enterocolitis [1, 2, 3]. Patent ductus arteriosus is a common cause of low diastolic blood pressure (BP) as a result of the diastolic outflow of blood into the pulmonary circulation from the left-to-right (L-R) shunt, which makes it difficult to treat [4]. Therefore, pharmacotherapy should be adjusted according to the pathophysiology of the condition that caused hypotension [1, 5, 6]. We report a case of an extremely preterm neonate with severe and persistent hypotension caused by hemodynamically significant PDA.

**CASE REPORT**

The preterm female neonate was delivered vaginally at 24<sup>1/7</sup> weeks of gestation with a birth weight of 710 g and an Apgar score of 3 in the first minute after birth. The pregnancy was properly controlled, complicated by the

mother's vaginal bleeding one month before delivery. There was no infection during pregnancy. Immediately after birth, the neonate was intubated. In the Neonatal Intensive Care Unit (NICU) in the Maternity Hospital, the neonate was placed on conventional mechanical ventilation (MV) and surfactant was administered. The neonate received dual antibiotic therapy (ampicillin and gentamicin) and total parenteral nutrition. In order to stimulate breathing, a preparation of methylxanthine, caffeine, was used. Because of hypotension, the neonate received a fluid bolus and during the first three days of life (DOL), inotropic support with dopamine was applied. Also, the neonate received a red blood cell transfusion in order to correct anemia.

The neonate was admitted to the Institute of Neonatology on the fourth DOL, in severe condition, orotracheally intubated, with a weight of 590 g, heart rate (HR) of 126 beats/min, BP of 61/28/41 mmHg and respiratory rate of 52 breaths/min. Oxygen saturation (SpO<sub>2</sub>) was 94% on MV with a fraction of inspired oxygen (FiO<sub>2</sub>) of 0.4. In our NICU, conventional MV was continued. Blood gas analysis showed metabolic acidosis. Chest X-ray showed signs of respiratory distress syndrome with moderate cardiomegaly. In the following hours after admission to the Institute, hypotension, predominantly diastolic hypotension, and oliguria were noted in the neonate, so inotropic support with dopamine and dobutamine in minimal

**Received • Примљено:**  
July 11, 2024

**Revised • Ревизија:**  
August 30, 2025

**Accepted • Прихваћено:**  
September 13, 2025

**Online first:** September 17, 2025

**Correspondence to:**

Ilija PALIĆ  
Kralja Milutina 50  
11000 Belgrade, Serbia  
[palicilija152@gmail.com](mailto:palicilija152@gmail.com)

doses was started. At the same time, cardiac auscultation was normal, without heart murmurs. Despite increasing the dose of dopamine and dobutamine, the hypotension was persistent (minimal diastolic BP was 10 mmHg), so on the second day of hospitalization, the administration of epinephrine was started. Echocardiography showed PDA measuring 2 mm with a L–R shunt of blood flow, as well as signs of heart failure. There was massive regurgitation of both AV valves. Also, patent foramen ovale was present, with an L–R shunt of blood flow. Because of acute kidney injury (stage 3 KDIGO classification) and green gastric residuals, ibuprofen was not used to close PDA. Restriction of total fluid intake (120 ml/kg per day) was applied. In accordance with BP values and diuresis, the dose of epinephrine was gradually increased to the maximum. After a short phase of maintaining stable BP values and diuresis at maximum doses of epinephrine, a gradual reduction in the dose of epinephrine was started. Diastolic hypotension then occurred again, so at the end of the first week of hospitalization, in addition to epinephrine, hydrocortisone was introduced for the therapy of hypotension. In the following days, the doses of epinephrine and hydrocortisone were gradually titrated. Control echocardiography was performed four days after the first examination and the findings showed no significant changes. Because of heart failure, intermittent administration of loop diuretics such as furosemide was started. In order to treat hypotension and stimulate diuresis, the neonate still required very high doses of inotropes and hydrocortisone. Control echocardiography findings were without significant changes. At the end of the third week of hospitalization, we began gradually reducing the doses of inotropes based on BP values and diuresis. In order to maintain normal BP values, hydrocortisone was administered until the end of the fourth week of hospitalization in minimal daily doses. BP values, as well as the inotropic and/or vasopressor therapy applied in our case, are shown in Table 1. When the neonate was hemodynamically stabilized, a cardiosurgical evaluation was performed. Surgical ligation of PDA was performed on the 43rd DOL without complications.

The neonate was on conventional MV for 46 days, then on non-invasive respiratory support (nasal continuous positive airway pressure) for 10 days and further on oxygen therapy until the age of two months (corrected 36 weeks of gestation). Sepsis screening was positive for late-onset sepsis for *Staphylococcus haemolyticus*. The

head ultrasound on the seventh DOL showed cerebellar hemorrhage. During a control head ultrasound, a gradual reduction of cerebellar hemorrhage was observed. Because of neonatal seizures, the neonate was treated with phenobarbital and midazolam. Electroencephalography (EEG) showed irregularity and depression of basic activity with epileptic discharges. On control EEG examinations, there were no epileptic discharges, the neonate had no neonatal seizures, so she was discharged home without antiseizure medications. During hospitalization, the neonate received five red blood cell transfusions and one platelet transfusion. Minimal enteral nutrition was started at the end of the second week of life. Full enteral nutrition was achieved in the 6th week of hospitalization. At the age of two months and 10 days, due to retinopathy of prematurity (ROP) intravitreal application of anti-VEGF was performed. The neonate was discharged home in the fourth month of life (corrected 40 weeks of gestation) with a weight of 2700 g (less than the 10th percentile for the gestational age).

**Ethics:** The manuscript has been written in accordance with the ethical standards of the Declaration of Helsinki. The publication of the data in the manuscript was approved by the Ethics Committee of the Institute of Neonatology (No. 2398/3).

DISCUSSION

After birth, there are complex and sudden changes that mostly affect the cardiovascular and respiratory system. In healthy full-term neonates, rapid closure of the ductus arteriosus occurs at birth, which is one of the key changes during the transition from fetal to neonatal circulation. However, in preterm neonates, constriction and permanent closure of the ductus arteriosus at birth are delayed, which may be associated with neonatal morbidity and mortality. The risk for PDA is inversely proportional to the gestational age. It is estimated that about 87% of neonates born at 24 weeks of gestation have a symptomatic PDA [3, 7, 8].

Hypotension is especially common in preterm neonates during the first 72 hours of life, as a result of large transient adaptive changes in the respiratory, cardiovascular and neuroendocrine systems. There is wide variation in the definition of hypotension in preterm neonates. One of the most common definitions of hypotension in preterm

**Table 1.** Blood pressure values and inotropic and/or vasopressor therapy in our patient

|                                |    |                  |                  |                  |                  |                  |                  |                  |
|--------------------------------|----|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| First week of hospitalization  | BP | 37/12            | 37/11            | 43/15            | 42/15            | 32/10            | 41/16            | 40/17            |
|                                | Th | dop + dob        | dop + dob        | epi              | epi              | epi              | epi              | epi + hydr       |
| Second week of hospitalization | BP | 36/17            | 46/20            | 58/22            | 37/18            | 46/23            | 49/26            | 44/15            |
|                                | Th | epi + hydr       | epi + hydr       | epi + hydr       | epi + hydr       | epi + hydr       | epi + hydr       | dop + dob + hydr |
| Third week of hospitalization  | BP | 42/19            | 50/25            | 63/32            | 56/21            | 44/22            | 51/29            | 43/16            |
|                                | Th | dop + dob + hydr | dop + dob + hydr | dop + dob + hydr | dop + dob + hydr | dop + dob + hydr | dop + dob + hydr | dop + dob + hydr |
| Fourth week of hospitalization | BP | 56/20            | 52/30            | 56/24            | 51/20            | 59/27            | 64/35            | 64/34            |
|                                | Th | dop + dob + hydr | dop + dob + hydr | dop + dob + hydr | dop + dob + hydr | hydr             | hydr             |                  |

BP – blood pressure; Th – therapy; dop – dopamine; dob – dobutamine; epi – epinephrine; hydr – hydrocortisone

neonates used in clinical practice is given by the British Association of Perinatal Medicine. According to this association, hypotension is defined as a value of mean BP that is less than the weeks of gestation. According to another definition, hypotension in preterm neonates is defined as mean BP below the 5th or 10th percentile for the weeks of gestation and postnatal age. Also, hypotension in preterm neonates is defined as a mean BP value below 30 mmHg. This definition is particularly useful for neonates after 72 hours of life [1, 6]. Hypotension associated with PDA can be challenging and difficult to treat [4, 9].

Preterm neonates are usually treated for hypotension in the first 24 hours of life. Batton et al. [10] in a prospective observational study showed that 55% of extremely preterm neonates received therapy for hypotension and 28% received a vasoactive medication. Our patient was an extremely preterm female neonate and had hypotension within 24 hours of life, so she received a fluid bolus and dopamine in the Maternity Hospital. The first-line therapy for hypotension in preterm neonates in many NICUs is the administration of a fluid bolus followed by inotropes such as dopamine. However, in neonates with PDA and heart failure a fluid bolus in hypotension therapy might be harmful. Also, dopamine, although it increases BP, can have a negative effect on cerebral perfusion and cerebral autoregulation in very low birth weight neonates (birth weight < 1500 g), which can increase the risk of intraventricular hemorrhage [6, 9, 11].

In accordance with the guidelines and recommendations, if hypotension is caused by myocardial dysfunction, the first-line therapy is dobutamine, which achieves its effect by stimulating  $\beta$ -1 adrenergic receptors [12]. Dobutamine increases myocardial contractility, HR, right and left ventricular output and mean BP. As a second-line therapy, we should consider dopamine, whose effect on BP and different organs is dose-dependent. In doses that are most often used in NICUs, 3–10  $\mu\text{g/kg/min}$ , by stimulating adrenergic and dopaminergic receptors, dopamine increases HR, myocardial contractility and BP [1, 6].

Epinephrine is the third-line therapy for severe and persistent hypotension caused by myocardial dysfunction. Its hemodynamic effects, achieved through alpha and beta adrenergic receptors, are dose-dependent. In low doses (0.01–0.1)  $\mu\text{g/kg/min}$  epinephrine stimulates the  $\alpha$ -2,  $\beta$ -1, and  $\beta$ -2 adrenergic receptors, which causes peripheral vasodilatation, increased myocardial contractility and HR, and finally increases BP. At higher doses (> 0.1)  $\mu\text{g/kg/min}$  epinephrine achieves effects through  $\alpha$ -1 adrenergic receptors whose activation causes peripheral vasoconstriction and increased HR [1, 6, 12]. Also, corticosteroids, such as hydrocortisone, are used as adjunctive or rescue therapy for refractory hypotension in preterm neonates, i.e., neonates who are hypotensive despite the administration of two inotropes. Their short-term use seems safe; however, a question is raised about their impact on neurodevelopmental outcome in preterm neonates [13, 14].

In addition to dopamine, dobutamine and epinephrine, norepinephrine is also used in the therapy of hypotension in neonates. Norepinephrine is an endogenous

sympathomimetic that is a potent  $\alpha$ -1 agonist, with moderate to weak effects on  $\beta$ -1 and  $\beta$ -2 adrenergic receptors. Because the effect on  $\beta$ -2 adrenergic receptors is minimal, norepinephrine has combined inotropic and peripheral vasoconstrictive effects. Norepinephrine is recommended as first-line treatment for septic shock in adults, children, and full-term neonates [15]. It is used in less than 5% of preterm neonates with shock as second- or third-line therapy [16, 17]. Preterm neonates have been shown to have higher levels of catecholamines, which may account for a weaker response to norepinephrine [18]. Although the effect of norepinephrine on BP in preterm and full-term neonates with septic shock, pulmonary hypertension or isolated systemic hypotension has been confirmed in several retrospective studies with significant improvement in diuresis, arterial blood gas values and tissue perfusion, in clinical practice it is traditionally used as second- or third-line therapy or as an adjuvant anti-hypotensive drug [19].

Milrinone is a type III phosphodiesterase inhibitor that acts on the myocardium by increasing intracellular concentrations of cyclic AMP and calcium by inhibiting the breakdown of cAMP. It has positive inotropic and lusitropic effects on the myocardium, while reducing systemic and pulmonary vascular resistance [20]. Clinical studies on the use of milrinone in neonates have mainly focused on the treatment of persistent pulmonary hypertension of the newborn, postoperative use after corrective cardiac surgery, and prevention and treatment of low left ventricular output syndrome after PDA ligation. However, the use of this drug also carries a risk of severe hypotension [21, 22].

Vasopressin is also used in the treatment of hypotension. It is synthesized as a prohormone, primarily in hypothalamic neurons. It plays a key role in the control of BP, osmotic balance, kidney function and sodium homeostasis. More recent clinical studies have confirmed the efficacy of vasopressin as rescue therapy in neonates with persistent pulmonary hypertension of the newborn and catecholamine-refractory hypotension [23].

Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitizer with positive inotropic and vasodilatory properties. It achieves its inotropic effect by selectively binding to cardiac troponin, improving myocardial contractility by increasing the sensitivity of contractile myofilaments to intracellular calcium. Data on the use of levosimendan in neonates and children are limited. Relevant systematic reviews have reported good effects on cardiac functions, but there is no significant difference in hemodynamic effects compared to standard inotropic therapy (including dopamine, dobutamine and milrinone). Some studies have shown a potentially positive effect on cardiovascular function in preterm neonates with pulmonary hypertension and its safety. Although in some studies it has shown promising effects in improving hemodynamics in neonates, its specific use for PDA-induced hypotension is not well established. Additional research is needed to determine its effectiveness and safety in the treatment of hypotension associated with PDA. For now, levosimendan remains an innovative therapeutic option for the treatment of severe cardiac dysfunction and pulmonary hypertension in preterm neonates [24, 25].



Clinical and laboratory findings in our case showed hemodynamically significant PDA, which was also confirmed by echocardiographic examination. There were contraindications for the use of ibuprofen in order to close the PDA. At that time, acetaminophen was not introduced in the Institute as a therapy for closing the PDA, so conservative treatment was applied. First of all, along with the previously started antihypotension therapy, fluid restriction was implemented with optimal ventilation, i.e., increasing positive end-expiratory pressure. Hemodynamic assessment of the patient was performed daily based on the clinical picture, blood gas analysis, serum lactate concentration, BP values and diuresis, with occasional echocardiographic examinations. Despite early recognition and conservative treatment of the PDA in our case, hypotension was persistent and severe, and its treatment lasted for four weeks of hospitalization. There was no effect on closing the PDA by

conservative treatment, so after achieving hemodynamic and respiratory stability, surgical ligation of the PDA was performed.

With advances in technology and neonatal intensive therapy and care, the survival of preterm neonates, especially extremely preterm neonates, has increased. Along with their survival, as a consequence of immaturity, neonatologists are increasingly encountering complications of premature birth in the early neonatal period, among which is hypotension. Knowing the cause, as well as the pathophysiology, allows the selection of the appropriate drug and proper treatment of hypotension in preterm neonates. In order to reduce the adverse effects of drugs, a gradual titration of the dose is required along with monitoring of the hemodynamic state of the neonate.

**Conflict of interest:** None declared.

## REFERENCES

- Sahni M, Jain S. Hypotension in neonates. *NeoReviews*. 2016;17(10):e579–89. [DOI: 10.1542/neo.17-10-e579]
- Mullaly R, El-Khuffash AF. Haemodynamic assessment and management of hypotension in the preterm. *Arch Dis Child Fetal Neonatal Ed*. 2024;109(2):120–7. [DOI: 10.1136/archdischild-2022-324935] [PMID: 37173119]
- Chakkarapani AA, Roehr CC, Hooper SB, Te Pas AB, Gupta S; ESPR Neonatal Resuscitation section writing group. Transitional circulation and hemodynamic monitoring in newborn infants. *Pediatr Res*. 2023;93(4):838–47. [DOI: 10.1038/s41390-022-02427-8] [PMID: 36593283]
- Manzar S. Patent ductus arteriosus and hypotension in a preterm infant: fluids or furosemide? *Fortune J Health Sci*. 2020;3(2):103–9. [DOI: 10.26502/fjhs011]
- Kalish BT. Management of neonatal hypotension. *Neonatal Netw*. 2017;36(1):40–7. [DOI: 10.1891/0730-0832.36.1.40] [PMID: 28137353]
- Agakidou E, Chatziioannidis I, Kontou A, Stathopoulou T, Chotas W, Sarafidis K. An update on pharmacologic management of neonatal hypotension: when, why, and which medication. *Children (Basel)*. 2024;11(4):490. [DOI: 10.3390/children11040490] [PMID: 38671707]
- Erdeve Ö, Okulu E, Singh Y, Sindelar R, Oncel MY, Terrin G, et al. An update on patent ductus arteriosus and what is coming next. *Turk Arch Pediatr*. 2022;57(2):118–31. [DOI: 10.5152/TurkArchPediatr.2022.21361] [PMID: 35383006]
- Chan B, Singh Y. Personalized evidence-based management of patent ductus arteriosus in preterm infants. *J Cardiovasc Dev Dis*. 2023;11(1):7. [DOI: 10.3390/jcdd11010007] [PMID: 38248877]
- Smith HA, Manzar S. Patent ductus arteriosus, hypotension, and fluid bolus in a preterm infant. *J Clin Cardiol Cardiovasc Interv*. 2020;3(7):074. [DOI: 10.31579/2641-0419/074]
- Batton B, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, et al. Use of antihypotensive therapies in extremely preterm infants. *Pediatrics*. 2013;131(6):e1865–73. [DOI: 10.1542/peds.2012-2779] [PMID: 23650301]
- Dempsey EM, Barrington KJ, Marlow N, O'Donnell CPF, Miletin J, Naulaers G, et al. Hypotension in preterm infants (HIP) randomised trial. *Arch Dis Child Fetal Neonatal Ed*. 2021;106(4):398–403. [DOI: 10.1136/archdischild-2020-320241] [PMID: 33627329]
- Vargo L, Seri I. New NANN practice guideline: the management of hypotension in the very-low-birth-weight infant. *Adv Neonatal Care*. 2011;11(4):272–8. [DOI: 10.1097/ANC.0b013e318229263c] [PMID: 22123349]
- Ibrahim H, Sinha IP, Subhedar NV. Corticosteroids for treating hypotension in preterm infants. *Cochrane Database Syst Rev*. 2011;(12):CD003662. [DOI: 10.1002/14651858.CD003662.pub4] [PMID: 22161379]
- Kharrat A, Diambomba Y, Jain A. Corticosteroid use in neonatal hypotension: a survey of Canadian neonatologists. *Pediatr Neonatol*. 2024;65(3):233–40. [DOI: 10.1016/j.pedneo.2023.09.013] [PMID: 38388227]
- Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. *Pediatr Crit Care Med*. 2020;21(2):e52–106. [DOI: 10.1097/PCC.0000000000002198] [PMID: 32032273]
- Stranak Z, Semberova J, Barrington K, O'Donnell C, Marlow N, Naulaers G, et al. International survey on diagnosis and management of hypotension in extremely preterm babies. *Eur J Pediatr*. 2014;173(6):793–8. [DOI: 10.1007/s00431-013-2251-9] [PMID: 24390060]
- Lu P, Sun Y, Gong X, Li Z, Hong W. Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study. *BMJ Paediatr Open*. 2023;7(1):e001804. [DOI: 10.1136/bmjpo-2022-001804] [PMID: 37045542]
- Mehandru PL, Assel BG, Nuamah IF, Fanaroff AA, Kalhan SC. Catecholamine response at birth in preterm newborns. *Biol Neonate*. 1993;64(2–3):82–8. [DOI: 10.1159/000243975] [PMID: 8260550]
- Rizk MY, Lapointe A, Lefebvre F, Barrington KJ. Norepinephrine infusion improves haemodynamics in the preterm infants during septic shock. *Acta Paediatr*. 2018;107(3):408–13. [DOI: 10.1111/apa.14112] [PMID: 28992392]
- Lozada Martinez ID, Bayona-Gamboa AJ, Meza-Fandiño DF, Paz-Echeverry OA, Ávila-Bonilla AM, Paz-Echeverry MJ, et al. Inotropic support in cardiogenic shock: who leads the battle, milrinone or dobutamine? *Ann Med Surg (Lond)*. 2022;82:104763. [DOI: 10.1016/j.amsu.2022.104763] [PMID: 36268289]
- Kitaoka H, Konishi T, Shitara Y, Ito A, Kashima K, Fujita A, et al. Effects of milrinone on neonates after patent ductus arteriosus ligation: a retrospective nationwide database study. *Neonatology*. 2023;120(6):751–9. [DOI: 10.1159/000533958] [PMID: 37757762]
- Sehgal A, Francis JV, Lewis AI. Use of milrinone in the management of haemodynamic instability following duct ligation. *Eur J Pediatr*. 2011;170(1):115–9. [DOI: 10.1007/s00431-010-1296-2] [PMID: 20848128]
- Khare C, Adhisivam B, Bhat BV, Vaishnav D. Utility of low dose vasopressin for persistent pulmonary hypertension of newborn with catecholamine refractory shock. *Indian J Pediatr*. 2021;88(5):450–4. [DOI: 10.1007/s12098-020-03519-1] [PMID: 33034000]
- Angadi U, Westrope C, Chowdhry MF. Is levosimendan effective in paediatric heart failure and post-cardiac surgeries? *Interact Cardiovasc Thorac Surg*. 2013;17(4):710–4. [DOI: 10.1093/icvts/ivt297] [PMID: 23832921]
- Hummel J, Rücker G, Stiller B. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease. *Cochrane Database Syst Rev*. 2017;3(3):CD011312. [DOI: 10.1002/14651858.CD011312.pub2] [PMID: 28262914]

## Изазови у лечењу хипотензије код екстремно незрелог новорођенчета

Илија Палић, Биљана Јовановић Кришуловић, Марија Јовичић, Мирослава Костић Тодоровић

Институт за неонатологију, Београд, Србија

### САЖЕТАК

**Увод** Хипотензија је честа код претерминске новорођенчади и последица је различитих фактора, као што су незрели миокард, транзитрна циркулација, перинатална хипоксија, вентилација позитивним притиском и релативна адренална инсуфицијенција. Водећи узроци хипотензије код претерминске новорођенчади су сепса и септични шок, отворен артеријски канал и некротизујући ентероколитис.

**Приказ болесника** Женско претерминско новорођенче рођено је у 24<sup>1/7</sup> недељи гестације, са телесном масом на рођењу од 710 g и Апгар скором 3 у првом минути после рођења. Хипотензија је регистрована од првог дана живота, па је примењиван допамин. Новорођенче је примљено у Институт за неонатологију у четвртом дану живота и настављена је терапија допамином и добутамином. Упркос повећању дозе, хипотензија је и даље била упорна, због чега је примењен адреналин. Ехокардиографски преглед је показао постојање отвореног артеријског канала и знакова срчане

инсуфицијенције. Стање новорођенчета било је компликовано акутним оштећењем бубрега. Због тога ибупрофен није коришћен у затварању отвореног артеријског канала, па је настављено његово конзервативно лечење. У циљу корекције хипотензије у терапију је додат хидрокортизон. Упркос конзервативном лечењу отвореног артеријског канала, хипотензија је била упорна и тешка, а њена терапија је трајала током четири недеље хоспитализације. Након постизања хемодинамске и респираторне стабилности, урађена је хируршка лигација отвореног артеријског канала.

**Закључак** Хипотензија је компликација у раном неонаталном периоду код екстремно незреле новорођенчади. Познавање узрока, као и патофизиологије, омогућава одабир одговарајућег лека и правилно лечење хипотензије код претерминске новорођенчади, што је за неонатологе веома изазовно.

**Кључне речи:** претерминско новорођенче; артеријски канал; хипотензија; кардиоваскуларни агенси